Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Findlay MC, Gandhoke GS, Davies JM, Knopman J, Smith KJ, Mokin M, Hassan AE, Harbaugh RE, Khalessi A, Fiehler J, Gross BA, Tarpley JW, Sivakumar W, Bain M, Crowley RW, Link TW, Fraser JF, Levitt MR, Chen PR, Hanel RA, Bernard JD, Jumaa M, Youssef P, Cress MC, Chaudry MI, Shakir HJ, Lesley WS, Billingsley J, Jones JG, Koch MJ, Paul AR, Mack WJ, Osbun JW, Dlouhy K, Grossberg JA, Kellner CP, Sahlein DH, Santarelli J, Schirmer CM, Liu JJ, Majjhoo AQ, Wolfe T, Patel NV, Roark C, Siddiqui AH, Grandhi R. Cost-Effectiveness of Adjunctive Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Secondary Analysis of EMBOLISE. AJNR Am J Neuroradiol. 2026 Oct 01; 47(10):2500-2509.
-
Joshi M, Kim K, Pickard AS, Sharp LK, Gerber BS, Touchette DR. Long-term cost-effectiveness of a mobile health intervention delivered by clinical pharmacists and community health workers for type 2 diabetes management in urban African American and Latinx populations. Am J Health Syst Pharm. 2026 04 07; 83(8):423-435.
-
Toan ATN, Phung TL, Tran-Duy A, Minh HV. Cost-Effectiveness of Add-On Ivabradine Versus Standard Pharmacotherapy in the Treatment of Heart Failure in Vietnam: An Analysis From a Health System Perspective. Value Health Reg Issues. 2026 Sep; 55:101594.
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
-
Montano-Campos JF, Adair JE, Basu A, Kyeyune RB, Bayigga L, Kityo-Mutuluuza C, Hansen R. Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda's context. Gene Ther. 2026 03; 33(2):109-117.
-
Généreux P, Reynolds MR, Kelley MA, Thompson C, Baron SJ. Cost-Effectiveness of TAVR Compared With Clinical Surveillance in Patients with Asymptomatic Severe Aortic Stenosis in the United States. Value Health. 2026 Jul; 29(7):1171-1179.
-
Gottimukkala KSV, Lane DD, Cunningham R, Malik HS, Jwa Y, Cassidy ME, Castelli JMP, Enstrom MR, Poljakov K, Gastelum G, Ho SH, Tassa C, Adair JE. CRISPR-AuNP: physicochemical optimization of a gold nanoparticle platform for cost-effective and modular non-viral gene editing in HSPCs. Gene Ther. 2026 03; 33(2):188-202.
-
Driver L, Walsh CD, Schissel C, Meguerdichian DA, Duggan NM, Baugh CW, Goldsmith AJ. Utilizing an ultrasound-guided nerve block for management of sciatica in the ED: A national simulation-based cost savings analysis. Am J Emerg Med. 2026 Mar; 101:135-140.
-
Juvekar P, Whitmore R. Cost Effectiveness in the Treatment of Lumbar Spondylolisthesis. Neurosurg Clin N Am. 2026 Jan; 37(1):93-102.
-
Choi SE, Simon L. Projected Outcomes of Removing Fluoride From US Public Water Systems. JAMA Health Forum. 2025 05 02; 6(5):e251166.